Cadila Pharma inks pact with Sweden's NovaSAID to develop new treatments

Cadila Pharmaceuticals has entered a tie-up with Sweden's NovaSAID AB to develop new treatments for inflammation and pain in conditions such as rheumatoid arthritis.

"The companies will collaborate around preclinical and clinical development of drug candidates that have been developed by NovaSAID and the development will be conducted at Cadila Pharmaceuticals' facility in Ahmedabad," Cadila Pharmaceuticals said in a statement.

According to the pact, all revenue generated from the sale and marketing of products covered by the agreement in India, Middle East and Africa, will be retained by Cadila and net sales in all other countries will be shared by the two companies.

Ahmedabad-based Cadila will bear all costs associated with the programme through to Phase II.

"We have entered this partnership combining scientific expertise of NovaSAID and our drug development capabilities to work towards novel solutions in treatment of pain and inflammation, which is one of the largest therapy areas," Cadila Pharmaceuticals CMD Rajiv Modi said.